Discover
ENGN
enGene Therapeutics Inc.
1.76
2 x 1.29
2 x 2.22
bid
ask
+
0.03
1.73%
2 @ 04:00 PM
1.76 +0.00 (0.00%)
| Ytd | -80.51% | |
| 1y | -51.38% |
1.73
day range
1.78
1.40
52 week range
12.25
| Open | 1.74 | Prev Close | 1.73 | Low | 1.73 | High | 1.78 | Mkt Cap | 117.90M |
| Vol | 605.23K | Avg Vol | 1.74M | EPS | -2.18 | P/E | N/A | Forward P/E | -3.53 |
| Beta | -0.76 | Short Ratio | 11.39 | Inst. Own | 83.23% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 09-14 | 50-d Avg | 3.15 | 200-d Avg | 6.95 | 1yr Est | 27.00 |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-23 | JMP Securities | Upgrade | Market Outperform | Market Outperform |
| 2024-12-23 | HC Wainwright & Co. | Upgrade | Buy | |
| 2024-12-06 | JMP Securities | Upgrade | Market Outperform | Market Outperform |
| 2024-11-27 | Raymond James | Upgrade | Outperform | |
| 2024-11-18 | JMP Securities | Upgrade | Market Outperform | |
| 2024-09-24 | Oppenheimer | Upgrade | Outperform | Outperform |
Profile
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a non-viral monotherapy to treat non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) in patients that have been unresponsive to treatment with Bacillus Calmette-Guérin (BCG). The company is based in Montreal, Canada.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-02-19 | BRUNK GERALD A | Director and Beneficial Owner of more than 10% of a Class of Security | 0.00 | Stock Award(Grant) |
| 2024-03-17 | CHEUNG ANTHONY TZEYEW | Chief Technology Officer | 102.87K | Conversion of Exercise of derivative security |
| 2024-09-26 | COOPER RONALD HAROLD WILFRED | Chief Executive Officer | 10.00K | Purchase |
| 2024-04-21 | FONDS DE SOLIDARITE DES TRAVAILLEURS DU | Beneficial Owner of more than 10% of a Class of Security | 3.04M | Sale |
| 2023-10-26 | FORBION GROWTH SPONSOR FEAC I B.V. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Conversion of Exercise of derivative security |
| 2024-05-27 | GLICKMAN RICHARD M | Director | 24.68K | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Fcpm III Services B.v. | 8.68M | 51.72M | 17.02% |
| 2024-09-29 | VR Adviser, LLC | 3.57M | 21.25M | 7.00% |
| 2024-09-29 | Blue Owl Capital Holdings LP | 3.06M | 18.23M | 6.00% |
| 2024-09-29 | Deep Track Capital, Lp | 2.61M | 15.54M | 5.12% |
| 2024-09-29 | Adage Capital Partners GP L.L.C. | 2.33M | 13.89M | 4.57% |
| 2024-09-29 | BVF Inc. | 2.25M | 13.42M | 4.42% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-07-30 | Franklin Strategic Series-Franklin Biotechnology Discove | 272.36K | 1.62M | 0.53% |
| 2024-10-30 | Fidelity NASDAQ Composite Index Fund | 27.52K | 164.00K | 0.05% |
| 2024-09-29 | Northern Small Cap Core Fund | 11.00K | 65.56K | 0.02% |
Dividend
| Dividend | Date |
|---|---|
| 0.13 | 2015-02-02 |
| 0.14 | 2014-12-01 |
| 0.15 | 2014-11-03 |
| 0.15 | 2014-10-01 |
| 0.13 | 2014-05-01 |
| 0.12 | 2013-12-02 |